The Role of Inflammasomes in Adjuvant-Driven Humoral and Cellular Immune Responses

Muñoz‐Wolf, Natalia; McCluskey, Seán; Lavelle, Ed C.

doi:10.1016/b978-0-12-804019-5.00002-5

Cited by 6 publications

(14 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chitosan has potential vaccine adjuvant properties that were first reported by Nishimura K. and coauthors in 1984–1985 [59]. Later, different forms of chitosan (solutions, gels, powders, micro- and nanoparticles, multicomponent formulations for parenteral, and mucosal administrations) were used successfully as vaccine adjuvants [60].…”

Section: Adjuvant Familiesmentioning

confidence: 99%

Vaccine Adjuvants Derived from Marine Organisms

Sanina

2019

Biomolecules

View full text Add to dashboard Cite

Vaccine adjuvants help to enhance the immunogenicity of weak antigens. The adjuvant effect of certain substances was noted long ago (the 40s of the last century), and since then a large number of adjuvants belonging to different groups of chemicals have been studied. This review presents research data on the nonspecific action of substances originated from marine organisms, their derivatives and complexes, united by the name ‘adjuvants’. There are covered the mechanisms of their action, safety, as well as the practical use of adjuvants derived from marine hydrobionts in medical immunology and veterinary medicine to create modern vaccines that should be non-toxic and efficient. The present review is intended to briefly describe some important achievements in the use of marine resources to solve this important problem.

show abstract

Section: Adjuvant Familiesmentioning

confidence: 99%

Vaccine Adjuvants Derived from Marine Organisms

Sanina

2019

Biomolecules

View full text Add to dashboard Cite

show abstract

“…Together, the caspase-1-dependent cytokines have been shown to influence both the humoral and cellular arms of adaptive responses, and thus may be of relevance for immunogenicity provided by inflammasome-activating adjuvants. Inflammasomes may be of particular interest for vaccines targeting cell-mediated immunity [56], as this arm of immune response is the direct place of action for inflammasome-dependent cytokines. Together, the caspase-1-dependent cytokines have been shown to influence both the humoral and cellular arms of adaptive responses, and thus may be of relevance for immunogenicity provided by inflammasome-activating adjuvants.…”

Section: Inflammasome-mediated Activation Of Adaptive Immunitymentioning

confidence: 99%

Section: Inflammasome-mediated Activation Of Adaptive Immunitymentioning

confidence: 99%

“…Chitosan is a biocompatible and biodegradable cationic polymer obtained from chitin [ 56 ]. It has a good safety profile and has been shown to promote adjuvanticity through induction of Ag-specific IgG1/IgG2a and Th1/Th2/Th17 responses [ 155 ].…”

Section: Experimental Adjuvants That Activate Inflammasomesmentioning

confidence: 99%

“…Many synthetic adjuvants activate inflammasomes, typically in myeloid cells of the innate immune system. The best characterised inflammasome, NLRP3, is also the most common adjuvant target [ 56 ]. NLRP3 expression is induced in myeloid cells via nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-kB) signalling [ 57 ], upon recognition of microbial ligands, such as lipopolysaccharide (LPS) or its synthetic mimics.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Inflammasome-Mediated Immunogenicity of Clinical and Experimental Vaccine Adjuvants

et al. 2020

View full text Add to dashboard Cite

In modern vaccines, adjuvants can be sophisticated immunological tools to promote robust and long-lasting protection against prevalent diseases. However, there is an urgent need to improve immunogenicity of vaccines in order to protect mankind from life-threatening diseases such as AIDS, malaria or, most recently, COVID-19. Therefore, it is important to understand the cellular and molecular mechanisms of action of vaccine adjuvants, which generally trigger the innate immune system to enhance signal transition to adaptive immunity, resulting in pathogen-specific protection. Thus, improved understanding of vaccine adjuvant mechanisms may aid in the design of “intelligent” vaccines to provide robust protection from pathogens. Various commonly used clinical adjuvants, such as aluminium salts, saponins or emulsions, have been identified as activators of inflammasomes - multiprotein signalling platforms that drive activation of inflammatory caspases, resulting in secretion of pro-inflammatory cytokines of the IL-1 family. Importantly, these cytokines affect the cellular and humoral arms of adaptive immunity, which indicates that inflammasomes represent a valuable target of vaccine adjuvants. In this review, we highlight the impact of different inflammasomes on vaccine adjuvant-induced immune responses regarding their mechanisms and immunogenicity. In this context, we focus on clinically relevant adjuvants that have been shown to activate the NLRP3 inflammasome and also present various experimental adjuvants that activate the NLRP3-, NLRC4-, AIM2-, pyrin-, or non-canonical inflammasomes and could have the potential to improve future vaccines. Together, we provide a comprehensive overview on vaccine adjuvants that are known, or suggested, to promote immunogenicity through inflammasome-mediated signalling.

show abstract

Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy

2022

View full text Add to dashboard Cite

The stimulator of interferon genes (STING) cellular signaling pathway is a promising target for cancer immunotherapy. Activation of the intracellular STING protein triggers the production of a multifaceted array of immunostimulatory molecules, which, in the proper context, can drive dendritic cell maturation, antitumor macrophage polarization, T cell priming and activation, natural killer cell activation, vascular reprogramming, and/or cancer cell death, resulting in immune-mediated tumor elimination and generation of antitumor immune memory. Accordingly, there is a significant amount of ongoing preclinical and clinical research toward further understanding the role of the STING pathway in cancer immune surveillance as well as the development of modulators of the pathway as a strategy to stimulate antitumor immunity. Yet, the efficacy of STING pathway agonists is limited by many drug delivery and pharmacological challenges. Depending on the class of STING agonist and the desired administration route, these may include poor drug stability, immunocellular toxicity, immune-related adverse events, limited tumor or lymph node targeting and/or retention, low cellular uptake and intracellular delivery, and a complex dependence on the magnitude and kinetics of STING signaling. This review provides a concise summary of the STING pathway, highlighting recent biological developments, immunological consequences, and implications for drug delivery. This review also offers a critical analysis of an expanding arsenal of chemical strategies that are being employed to enhance the efficacy, safety, and/or clinical utility of STING pathway agonists and lastly draws attention to several opportunities for therapeutic advancements.

show abstract

The Role of Inflammasomes in Adjuvant-Driven Humoral and Cellular Immune Responses

Cited by 6 publications

References 100 publications

Vaccine Adjuvants Derived from Marine Organisms

Vaccine Adjuvants Derived from Marine Organisms

Inflammasome-Mediated Immunogenicity of Clinical and Experimental Vaccine Adjuvants

Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy

Contact Info

Product

Resources

About